Angiogenesis in melanoma: an update with a focus on current targeted therapies

被引:57
|
作者
Jour, George [1 ]
Ivan, Doina [1 ]
Aung, Phyu P. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 0085,1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; PRIMARY CUTANEOUS MELANOMA; MATRIX-METALLOPROTEINASE INHIBITOR; METASTATIC MALIGNANT-MELANOMA; VON-WILLEBRAND-FACTOR; PRIMARY TUMOR-GROWTH; STAGE IV MELANOMA; PHASE-II; IN-VIVO; VASCULOGENIC MIMICRY;
D O I
10.1136/jclinpath-2015-203482
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Angiogenesis plays a crucial role in melanoma metastasis and progression. In recent years, numerous studies have investigated the prognostic and clinical significance of this phenomenon, and the development of molecular techniques has enabled us to achieve a better understanding of angiogenesis in melanoma. Herein, we review the current state of knowledge regarding angiogenesis in melanoma, including the pathophysiological, histological and immunohistochemical aspects of this phenomenon. We also review the molecular pathways involved in angiogenesis and the interplay between different components that might be manipulated in the future development of efficient targeted therapies. Recently developed targeted antiangiogenic therapies in clinical trials and included in the treatment of advanced-stage melanoma are also reviewed.
引用
收藏
页码:472 / 483
页数:12
相关论文
共 50 条
  • [41] Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists
    Kakavand, Hojabr
    Wilmott, James S.
    Long, Georgina V.
    Scolyer, Richard A.
    PATHOLOGY, 2016, 48 (02) : 194 - 202
  • [42] Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies
    Chung, Hye Jin
    Mahalingam, Meera
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (05) : 621 - 639
  • [43] Overview of current melanoma therapies
    Fateeva, Anna
    Eddy, Kevinn
    Chen, Suzie
    PIGMENT CELL & MELANOMA RESEARCH, 2024, 37 (05) : 562 - 568
  • [44] Current Systemic Therapies for Melanoma
    Palathinkal, Darren M.
    Sharma, Timmie R.
    Koon, Henry B.
    Bordeaux, Jeremy S.
    DERMATOLOGIC SURGERY, 2014, 40 (09) : 948 - 963
  • [45] Current targeted therapies in lymphomas
    Chung, Clement
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (22) : 1825 - 1834
  • [46] Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma
    Christiansen, Shelly A.
    Khan, Shaheer
    Gibney, Geoffrey T.
    CANCER JOURNAL, 2017, 23 (01): : 59 - 62
  • [47] An Update on the Role of Ubiquitination in Melanoma Development and Therapies
    Soysouvanh, Frederic
    Giuliano, Serena
    Habel, Nadia
    El-Hachem, Najla
    Pisibon, Celine
    Bertolotto, Corine
    Ballotti, Robert
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (05) : 1 - 20
  • [48] Targeted therapies in rheumatoid arthritis: Focus on rituximab
    Teng, Y. K. O.
    Huizinga, T. W. J.
    van Laar, J. M.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 325 - 333
  • [49] Metastatic gastric cancer - focus on targeted therapies
    Meza-Junco, Judith
    Sawyer, Michael B.
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 137 - 146
  • [50] Targeted Therapies in Psoriatic Arthritis-An Update
    Sundanum, Sonia
    Orr, Carl
    Veale, Douglas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)